BridgeBio Pharma Inc (BBIO)
28.01
-0.84
(-2.91%)
USD |
NASDAQ |
May 31, 16:00
28.01
0.00 (0.00%)
After-Hours: 20:00
BridgeBio Pharma Research and Development Expense (TTM): 503.82M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 503.82M |
| December 31, 2023 | 455.71M |
| September 30, 2023 | 416.39M |
| June 30, 2023 | 383.76M |
| March 31, 2023 | 384.67M |
| December 31, 2022 | 399.46M |
| September 30, 2022 | 430.76M |
| June 30, 2022 | 442.55M |
| March 31, 2022 | 436.11M |
| December 31, 2021 | 451.02M |
| September 30, 2021 | 419.00M |
| Date | Value |
|---|---|
| June 30, 2021 | 406.74M |
| March 31, 2021 | 391.38M |
| December 31, 2020 | 337.05M |
| September 30, 2020 | 304.36M |
| June 30, 2020 | 267.59M |
| March 31, 2020 | 233.32M |
| December 31, 2019 | 209.95M |
| September 30, 2019 | 203.66M |
| June 30, 2019 | 179.53M |
| March 31, 2019 | 151.10M |
| December 31, 2018 | 140.07M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
179.53M
Minimum
Jun 2019
503.82M
Maximum
Mar 2024
362.84M
Average
395.42M
Median
Research and Development Expense (TTM) Benchmarks
| Pfizer Inc | 10.67B |
| Alnylam Pharmaceuticals Inc | 1.035B |
| Regenxbio Inc | 228.59M |
| Arvinas Inc | 368.80M |
| IDEAYA Biosciences Inc | 144.45M |